A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome

Acute Lung Injury ◽

Lung Injury ◽

Active Site ◽

Distress Syndrome ◽

Recombinant Factor Viia ◽

Factor Viia ◽

Double Blind ◽

Safety And Efficacy ◽

Faculty Opinions recommendation of A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1162202.622674 ◽

2009 ◽

Author(s):

Michael O'Connor

Keyword(s):

Acute Lung Injury ◽

Lung Injury ◽

Active Site ◽

Distress Syndrome ◽

Recombinant Factor Viia ◽

Factor Viia ◽

Double Blind ◽

Safety And Efficacy ◽

A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome*

Critical Care Medicine ◽

10.1097/ccm.0b013e31819fff2c ◽

2009 ◽

Vol 37 (6) ◽

pp. 1874-1880 ◽

Cited By ~ 29

Author(s):

Jean-Louis Vincent ◽

Antonio Artigas ◽

Lars C. Petersen ◽

Christian Meyer

Keyword(s):

Acute Lung Injury ◽

Lung Injury ◽

Active Site ◽

Distress Syndrome ◽

Recombinant Factor Viia ◽

Factor Viia ◽

Double Blind ◽

Safety And Efficacy ◽

A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome

Yearbook of Critical Care Medicine ◽

10.1016/s0734-3299(10)79374-6 ◽

2010 ◽

Vol 2010 ◽

pp. 8-9

Author(s):

R.P. Dellinger

Keyword(s):

Acute Lung Injury ◽

Lung Injury ◽

Active Site ◽

Distress Syndrome ◽

Recombinant Factor Viia ◽

Factor Viia ◽

Double Blind ◽

Safety And Efficacy ◽

Faculty Opinions recommendation of A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1104277.560282 ◽

2008 ◽

Author(s):

Jozef Kesecioglu

Keyword(s):

Carboxylic Acid ◽

Respiratory Distress ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome*

Critical Care Medicine ◽

10.1097/ccm.0b013e318164e7e4 ◽

2008 ◽

Vol 36 (3) ◽

pp. 782-788 ◽

Cited By ~ 20

Author(s):

Peter E. Morris ◽

Peter Papadakos ◽

James A. Russell ◽

Richard Wunderink ◽

Daniel P. Schuster ◽

...

Keyword(s):

Carboxylic Acid ◽

Respiratory Distress ◽

Distress Syndrome ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽

Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1/2 trial

Intensive Care Medicine ◽

10.1007/s00134-021-06570-4 ◽

2021 ◽

Author(s):

G. Bellingan ◽

F. Jacono ◽

J. Bannard-Smith ◽

D. Brealey ◽

N. Meyer ◽

...

Keyword(s):

Multipotent Adult Progenitor Cells

Respiratory Distress ◽

Progenitor Cells ◽

Distress Syndrome ◽

Phase 1 ◽

Double Blind ◽

Safety And Efficacy ◽

Double Blind Placebo ◽

Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome

Health Technology Assessment ◽

10.3310/hta17380 ◽

2013 ◽

Vol 17 (38) ◽

Cited By ~ 20

Author(s):

S Gates ◽

GD Perkins ◽

SE Lamb ◽

C Kelly ◽

DR Thickett ◽

...

Keyword(s):

Economic Evaluation ◽

Lung Injury ◽

Respiratory Distress ◽

Distress Syndrome ◽

Controlled Trial ◽

Beta Agonist ◽

Double Blind ◽

Beta Agonist Lung Injury TrIal-2 (BALTI-2) trial protocol: A randomised, double-blind, placebo-controlled of intravenous infusion of salbutamol in the acute respiratory distress syndrome

Trials ◽

10.1186/1745-6215-12-113 ◽

2011 ◽

Vol 12 (1) ◽

Cited By ~ 16

Author(s):

Gavin D Perkins ◽

Simon Gates ◽

Sarah E Lamb ◽

Chris McCabe ◽

Duncan Young ◽

...

Keyword(s):

Lung Injury ◽

Respiratory Distress ◽

Intravenous Infusion ◽

Distress Syndrome ◽

Beta Agonist ◽

Trial Protocol ◽

Double Blind ◽

Faculty Opinions recommendation of Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1102307.558341 ◽

2008 ◽

Author(s):

Claude Guerin

Keyword(s):

Randomized Controlled Trial ◽

Acute Lung Injury ◽

Lung Injury ◽

Distress Syndrome ◽

Controlled Trial ◽

Positive End Expiratory Pressure ◽

Pressure Setting ◽

Randomized Controlled

Faculty Opinions recommendation of Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1159559.619942 ◽

2009 ◽

Author(s):

Herwig Gerlach

Keyword(s):

Systematic Review ◽

Acute Lung Injury ◽

Lung Injury ◽

Respiratory Distress ◽

Distress Syndrome ◽

Meta Analysis